# A remarkable year for NSCLC: Seven new FDA approvals in 2025 across molecular targets

**Authors:** Krešimir Tomić, Semir Vranić

PMC · DOI: 10.17305/bb.2026.13832 · 2026-01-05

## Full-text entities

- **Genes:** SLTM (SAFB like transcription modulator) [NCBI Gene 79811] {aka Met}, ROS1 (ROS proto-oncogene 1, receptor tyrosine kinase) [NCBI Gene 6098] {aka MCF3, ROS, c-ros-1}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, TACSTD2 (tumor associated calcium signal transducer 2) [NCBI Gene 4070] {aka EGP-1, EGP1, GA733-1, GA7331, GP50, M1S1}
- **Diseases:** cancer (MESH:D009369), NSCLC (MESH:D002289)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12873738/full.md

---
Source: https://tomesphere.com/paper/PMC12873738